Edition:
United States

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

5.49USD
20 Apr 2018
Change (% chg)

$-0.17 (-3.00%)
Prev Close
$5.66
Open
$5.62
Day's High
$5.67
Day's Low
$5.47
Volume
218,023
Avg. Vol
303,616
52-wk High
$5.85
52-wk Low
$1.93

Select another date:

Mon, Apr 2 2018

BRIEF-Cerus’ Redes Phase 3 Red Blood Cell Study Expands Into The Continental U.S.

* ’ REDES PHASE 3 RED BLOOD CELL STUDY EXPANDS INTO THE CONTINENTAL U.S.

BRIEF-Cerus Announces The Fourth Biologics License Application Approval For A U.S. Blood Center Customer

* CERUS ANNOUNCES THE FOURTH BIOLOGICS LICENSE APPLICATION (BLA) APPROVAL FOR A U.S. BLOOD CENTER CUSTOMER

BRIEF-Cerus Corp Reports Q4 Loss Per Share $0.10

* ORATION REPORTS RECORD FOURTH QUARTER AND YEAR END 2017 RESULTS

BRIEF-Cerus Announces Pricing Of Public Offering Of Common Stock

* CERUS CORP - ‍PRICING OF PUBLIC OFFERING OF ITS COMMON STOCK FOR PROCEEDS OF $50.0 MILLION, BEFORE DEDUCTING ESTIMATED OFFERING EXPENSES PAYABLE BY CERUS​ Source text for Eikon: Further company coverage:

BRIEF-Cerus Announces Public Offering Of Common Stock

* CERUS CORP - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Cerus - Chronic Anemia Phase 3 Study Met Primary Efficacy And Safety Endpoints

* CERUS REPORTS POSITIVE TOP-LINE RESULTS FROM CHRONIC ANEMIA PHASE 3 STUDY EVALUATING INTERCEPT RED BLOOD CELLS IN THALASSEMIA PATIENTS

BRIEF-Cerus Corp Expects Full Year 2017 Product Revenue To Be $43.6 Million

* CERUS CORP - CERUS' UNAUDITED PRELIMINARY PRODUCT REVENUE FOR Q4 OF 2017 WAS $16.2 MILLION

BRIEF-Cerus receives IDE approval to initiate phase iii recepi study

* Cerus Corporation receives IDE approval to initiate phase iii recepi study Source text for Eikon: Further company coverage:

BRIEF-Cerus Corp reports Q3 loss per share $0.12

* Q3 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S

BRIEF-Cerus and Kedrion Biopharma enter distribution agreement for full INTERCEPT blood system portfolio

* Cerus and Kedrion Biopharma enter distribution agreement for the full INTERCEPT blood system portfolio in Italy

Select another date: